Volume 68, Issue 6, Pages 939-945 (December 2015) Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells  Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan, Mai Van, Annemieke J.M. Nieuweboer, Ron H.J. Mathijssen, Paul Hamberg, Hielke J. Meulenbeld, Bram De Laere, Luc Y. Dirix, Robert J. van Soest, Martijn P. Lolkema, John W.M. Martens, Wytske M. van Weerden, Guido W. Jenster, John A. Foekens, Ronald de Wit, Stefan Sleijfer  European Urology  Volume 68, Issue 6, Pages 939-945 (December 2015) DOI: 10.1016/j.eururo.2015.07.007 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Study flow chart showing the selection of patients for the analyses. Cq=cycle threshold for quantification; CTC=circulating tumor cell. European Urology 2015 68, 939-945DOI: (10.1016/j.eururo.2015.07.007) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 2 Waterfall plots of prostate-specific antigen (PSA) responses to cabazitaxel treatment (A) after 12 wk and (B) at the end of treatment. The dashed lines represent 30% and 50% decreases in PSA level relative to the baseline level. No differences in PSA responses were observed between AR-V7–positive and AR-V7–negative patients. Sequential PSA values from three patients were missing (two AR-V7 positive and one negative). One AR-V7–positive patient discontinued treatment after two cycles of cabazitaxel and was not included in the analysis for PSA response after 12 wk. The AR-V7–negative patient was still undergoing treatment and thus was included only in the analysis for the PSA response after 12 wk. CTC=circulating tumor cell; PSA=prostate specific antigen. * Patients who were treated with abiraterone before cabazitaxel. European Urology 2015 68, 939-945DOI: (10.1016/j.eururo.2015.07.007) Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 3 (A) Progression-free survival and (B) overall survival as a function of AR-V7 in circulating tumor cells at baseline. The reported p value is from a log-rank test. AR-V7 =androgen receptor splice variant 7; CI=confidence interval; HR=hazard ratio. European Urology 2015 68, 939-945DOI: (10.1016/j.eururo.2015.07.007) Copyright © 2015 European Association of Urology Terms and Conditions